Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Glioblastoma 80Prostatic Neoplasms 57Breast Neoplasms 54Carcinoma, Non-Small-Cell Lung 53Esophageal Neoplasms 48Rectal Neoplasms 42Lung Neoplasms 41Squamous Cell Carcinoma of Head and Neck 33Head and Neck Neoplasms 33Brain Neoplasms 33Gliosarcoma 31Pancreatic Neoplasms 29Uterine Cervical Neoplasms 28Neoplasms 25Glioma 24Neoplasm Metastasis 23Sarcoma 22Oropharyngeal Neoplasms 21Melanoma 19Esophageal Squamous Cell Carcinoma 19Astrocytoma 18Adenocarcinoma Of Esophagus 15Stomach Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Squamous Cell 12Urinary Bladder Neoplasms 11Mouth Neoplasms 11Lymphoma, Follicular 11Central Nervous System Neoplasms 11Carcinoma 11

Interventions

Cyclophosphamide 14Dexamethasone 13Vincristine 11Cytarabine 11Methotrexate 9venetoclax 7Inotuzumab Ozogamicin 7Doxorubicin 7pegaspargase 6merphos 6blinatumomab 6Prednisone 6dexamethasone acetate 5dexamethasone 21-phosphate 5Mercaptopurine 5Calcium Dobesilate 5prednylidene 4deltacortene 4azathiopurine 4auricularum 4Specimen Handling 4Leucovorin 4Asparaginase 4Thioguanine 3Rituximab 3N,N-dicyclohexyl-isoborneol-10-sulfonamide 3Methylprednisolone 3fludarabine 2calaspargase pegol 2asparaginase erwinia chrysanthemi recombinant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Radiation × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡